{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:13Z","timestamp":1787387053905,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,22]]},"DOI":"10.7759\/cureus.114962","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:07:07Z","timestamp":1787386027000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Clinical Outcomes and Real-World Effectiveness of Tirzepatide in Adults With Overweight or Obesity: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Aliyu O","family":"Olaniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khyathi Krishna","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Happiness","family":"Olaniyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Agbonrofo Eboigbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susuti R","family":"Yerima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazeem","family":"Gabriels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher M","year":"2019","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019, 15:288-98. 10.1038\/s41574-019-0176-8","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","unstructured":"World Health Organization. Obesity and overweight. (2024). https.\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs A","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity management in adults: a review. JAMA. 2023, 330:2000-15. 10.1001\/jama.2023.19897","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70049","article-title":"Exploring the relationship between obesity, weight loss and health-related quality of life: an updated systematic review of reviews","volume":"16","author":"Fl\u00f8lo TN","year":"2026","unstructured":"Fl\u00f8lo TN, Liu HH, Andersen JR, Kolotkin RL. Exploring the relationship between obesity, weight loss and health-related quality of life: an updated systematic review of reviews. Clin Obes. 2026, 16:e70049. 10.1111\/cob.70049","journal-title":"Clin Obes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton S","year":"2020","unstructured":"Wharton S, Lau DC, Vallis M, et al.. Obesity in adults: a clinical practice guideline. CMAJ. 2020, 192:E875-91. 10.1503\/cmaj.191707","journal-title":"CMAJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden TA","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al.. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023, 29:2909-18. 10.1038\/s41591-023-02597-w","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008","article-title":"Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S167-80. 10.2337\/dc25-S008","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.08.012","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall KD","year":"2018","unstructured":"Hall KD, Kahan S. Maintenance of lost weight and long-term management of obesity. Med Clin North Am. 2018, 102:183-97. 10.1016\/j.mcna.2017.08.012","journal-title":"Med Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00887-4","article-title":"Obesity-induced and weight-loss-induced physiological factors affecting weight regain","volume":"19","author":"van Baak MA","year":"2023","unstructured":"van Baak MA, Mariman EC. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023, 19:655-70. 10.1038\/s41574-023-00887-4","journal-title":"Nat Rev Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00740-2","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity","volume":"18","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor agonist for the treatment of type 2 diabetes and obesity. Nat Rev Endocrinol. 2022, 18:701-2. 10.1038\/s41574-022-00740-2","journal-title":"Nat Rev Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00817-4","article-title":"Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases","volume":"19","author":"H\u00e6dersdal S","year":"2023","unstructured":"H\u00e6dersdal S, Andersen A, Knop FK, Vilsb\u00f8ll T. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases. Nat Rev Endocrinol. 2023, 19:321-35. 10.1038\/s41574-023-00817-4","journal-title":"Nat Rev Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of tirzepatide in Japanese adults with obesity disease (SURMOUNT-J): a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"13","author":"Kadowaki T","year":"2025","unstructured":"Kadowaki T, Kiyosue A, Shingaki T, Oura T, Yokote K. Efficacy and safety of tirzepatide in Japanese adults with obesity disease (SURMOUNT-J): a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025, 13:384-96. 10.1016\/S2213-8587(24)00377-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for obstructive sleep apnea in adults with obesity","volume":"391","author":"Malhotra A","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for obstructive sleep apnea in adults with obesity. N Engl J Med. 2024, 391:1193-205. 10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao L","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al.. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024, 332:551-60. 10.1001\/jama.2024.9217","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff AM","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, et al.. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025, 392:958-71. 10.1056\/NEJMoa2410819","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03340-2","article-title":"Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE)","volume":"42","author":"Ng CD","year":"2025","unstructured":"Ng CD, Divino V, Wang J, Toliver JC, Buss M. Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE). Adv Ther. 2025, 42:5468-80. 10.1007\/s12325-025-03340-2","journal-title":"Adv Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez PJ","year":"2024","unstructured":"Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, Brar R, Baker C, Gluckman TJ, Stucky NL. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024, 184:1056-64. 10.1001\/jamainternmed.2024.2525","journal-title":"JAMA Intern Med"},{"key":"ref22","article-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5","author":"Higgins JPT","year":"2024","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Cochrane, London, UK; 2024."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan - a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan - a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell M","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, et al.. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020, 368:l6890. 10.1136\/bmj.l6890","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey WT","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al.. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023, 402:613-26. 10.1016\/S0140-6736(23)01200-X","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look M","year":"2025","unstructured":"Look M, Dunn JP, Kushner RF, et al.. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025, 27:2720-9. 10.1111\/dom.16275","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0763","article-title":"Tirzepatide treatment and associated changes in \u03b2-cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: A post hoc analysis from the SURMOUNT-1 trial","volume":"48","author":"Mari A","year":"2025","unstructured":"Mari A, Stefanski A, van Raalte DH, et al.. Tirzepatide treatment and associated changes in \u03b2-cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: A post hoc analysis from the SURMOUNT-1 trial. Diabetes Care. 2025, 48:1622-7. 10.2337\/dc25-0763","journal-title":"Diabetes Care"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12734","article-title":"Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials","volume":"15","author":"Horn DB","year":"2025","unstructured":"Horn DB, Kahan S, Batterham RL, et al.. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025, 15:e12734. 10.1111\/cob.12734","journal-title":"Clin Obes"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16554","article-title":"Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1","volume":"27","author":"Ard J","year":"2025","unstructured":"Ard J, Lee CJ, Gudzune K, et al.. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab. 2025, 27:5064-71. 10.1111\/dom.16554","journal-title":"Diabetes Obes Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz HM","year":"2024","unstructured":"Krumholz HM, de Lemos JA, Sattar N, et al.. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 2024, 110:1165-71. 10.1136\/heartjnl-2024-324170","journal-title":"Heart"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m\u00b2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos JA","year":"2024","unstructured":"de Lemos JA, Linetzky B, le Roux CW, et al.. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m\u00b2: SURMOUNT-1 ambulatory blood pressure monitoring substudy. Hypertension. 2024, 81:e41-3. 10.1161\/HYPERTENSIONAHA.123.22022","journal-title":"Hypertension"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.04.044","article-title":"Comprehensive long-term changes in cardiovascular risk biomarkers with tirzepatide: a SURMOUNT-1 post hoc analysis","volume":"88","author":"Sattar N","year":"2026","unstructured":"Sattar N, Linetzky B, Ruotolo G, et al.. Comprehensive long-term changes in cardiovascular risk biomarkers with tirzepatide: a SURMOUNT-1 post hoc analysis. J Am Coll Cardiol. 2026, 88:652-66. 10.1016\/j.jacc.2026.04.044","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2026.101454","article-title":"Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials","volume":"26","author":"Sattar N","year":"2026","unstructured":"Sattar N, Lee CJ, Srinath R, et al.. Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials. Am J Prev Cardiol. 2026, 26:101454. 10.1016\/j.ajpc.2026.101454","journal-title":"Am J Prev Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70122","article-title":"Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT","volume":"34","author":"Wadden TA","year":"2026","unstructured":"Wadden TA, Oquendo MA, Kushner RF, Cao D, Karanikas CA, Kechter A, Murphy MA. Psychiatric safety of tirzepatide in people with obesity and no known major psychopathology: a post hoc analysis of SURMOUNT. Obesity (Silver Spring). 2026, 34:565-78. 10.1002\/oby.70122","journal-title":"Obesity (Silver Spring)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/oby.70067","article-title":"People with lowest physical functioning scores showed greatest improvement after tirzepatide treatment","volume":"34","author":"Li X","year":"2026","unstructured":"Li X, Cao D, Sapin H, et al.. People with lowest physical functioning scores showed greatest improvement after tirzepatide treatment. Obesity (Silver Spring). 2026, 34:114-26. 10.1002\/oby.70067","journal-title":"Obesity (Silver Spring)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24348","article-title":"Early-onset obesity and tirzepatide treatment: a post hoc analysis of the surmount clinical trials","volume":"33","author":"Gourgari E","year":"2025","unstructured":"Gourgari E, Srivastava G, Kelly AS, et al.. Early-onset obesity and tirzepatide treatment: a post hoc analysis of the surmount clinical trials. Obesity (Silver Spring). 2025, 33:1668-79. 10.1002\/oby.24348","journal-title":"Obesity (Silver Spring)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.71009","article-title":"Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials","volume":"28","author":"Kokkinos A","year":"2026","unstructured":"Kokkinos A, Thethi T, Lee CJ, et al.. Tirzepatide efficacy and tolerability according to early weight response: a post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials. Diabetes Obes Metab. 2026, 28:8367-77. 10.1111\/dom.71009","journal-title":"Diabetes Obes Metab"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.3274","article-title":"Weight changes with tirzepatide and concomitant weight-inducing medications: post hoc analysis of randomized clinical trials","volume":"9","author":"Galindo RJ","year":"2026","unstructured":"Galindo RJ, Gudzune KA, Look M, et al.. Weight changes with tirzepatide and concomitant weight-inducing medications: post hoc analysis of randomized clinical trials. JAMA Netw Open. 2026, 9:e263274. 10.1001\/jamanetworkopen.2026.3274","journal-title":"JAMA Netw Open"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2026.100248","article-title":"Nutritional status with tirzepatide in obesity: a post hoc analysis of the SURMOUNT-1-4 randomized clinical trials","volume":"17","author":"Almandoz JP","year":"2026","unstructured":"Almandoz JP, Pickett-Blakely O, Tewksbury C, et al.. Nutritional status with tirzepatide in obesity: a post hoc analysis of the SURMOUNT-1-4 randomized clinical trials. Obes Pillars. 2026, 17:100248. 10.1016\/j.obpill.2026.100248","journal-title":"Obes Pillars"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune KA","year":"2025","unstructured":"Gudzune KA, Stefanski A, Cao D, Mojdami D, Wang F, Ahmad N, Ling Poon J. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study. Diabetes Obes Metab. 2025, 27:539-50. 10.1111\/dom.16046","journal-title":"Diabetes Obes Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref46","article-title":"Chapter 14: Completing 'summary of findings' tables and grading the certainty of the evidence","author":"Sch\u00fcnemann HJ","year":"2024","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, et al.. Chapter 14: Completing 'summary of findings' tables and grading the certainty of the evidence. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5. Higgins JPT, Thomas J, Chandler J, et al. (ed): Cochrane, London, UK; 2024. https:\/\/www.cochrane.org\/handbook:"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85033","article-title":"Translational success and pharmacoeconomic lessons of pandemic-driven drug repurposing","volume":"17","author":"Elechi KW","year":"2025","unstructured":"Elechi KW, Adeoye AF, Olaniyi AO, et al.. Translational success and pharmacoeconomic lessons of pandemic-driven drug repurposing. Cureus. 2025, 17:e85033. 10.7759\/cureus.85033","journal-title":"Cureus"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.109309","article-title":"Risk factors for 30-day hospital readmission in patients with cancer: a systematic review with emphasis on older adults","volume":"18","author":"Nwabor GO","year":"2026","unstructured":"Nwabor GO, Subhani N, Weke D, Obianenue RC, Olaniyi H, Azeez OM, Olaniyi AO. Risk factors for 30-day hospital readmission in patients with cancer: a systematic review with emphasis on older adults. Cureus. 2026, 18:e109309. 10.7759\/cureus.109309","journal-title":"Cureus"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93790","article-title":"Effectiveness of aspirin plus dipyridamole versus clopidogrel in preventing recurrent ischemic stroke: a systematic review","volume":"17","author":"Osayagbon AE","year":"2025","unstructured":"Osayagbon AE, Olaniyi AO, Oyovwi J, Banerjee A, Lawal OP, Butt MA. Effectiveness of aspirin plus dipyridamole versus clopidogrel in preventing recurrent ischemic stroke: a systematic review. Cureus. 2025, 17:e93790. 10.7759\/cureus.93790","journal-title":"Cureus"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101740","article-title":"An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists","volume":"4","author":"Dani SS","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S, et al.. An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC Adv. 2025, 4:101740. 10.1016\/j.jacadv.2025.101740","journal-title":"JACC Adv"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0803-x","article-title":"Joint international consensus statement for ending stigma of obesity","volume":"26","author":"Rubino F","year":"2020","unstructured":"Rubino F, Puhl RM, Cummings DE, et al.. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020, 26:485-97. 10.1038\/s41591-020-0803-x","journal-title":"Nat Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250502","article-title":"Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update","volume":"197","author":"Pedersen SD","year":"2025","unstructured":"Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025, 197:E797-809. 10.1503\/cmaj.250502","journal-title":"CMAJ"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller TD","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022, 21:201-23. 10.1038\/s41573-021-00337-8","journal-title":"Nat Rev Drug Discov"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01919-X","article-title":"Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation","volume":"399","author":"Lingvay I","year":"2022","unstructured":"Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022, 399:394-405. 10.1016\/S0140-6736(21)01919-X","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00191-2","article-title":"There is no magic bullet for obesity","volume":"11","author":"Lingvay I","year":"2023","unstructured":"Lingvay I, Cohen RV, le Roux CW, Sumithran P. There is no magic bullet for obesity. Lancet Diabetes Endocrinol. 2023, 11:541-10. 10.1016\/S2213-8587(23)00191-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay I","year":"2024","unstructured":"Lingvay I, Cohen RV, Roux CW, Sumithran P. Obesity in adults. Lancet. 2024, 404:972-87. 10.1016\/S0140-6736(24)01210-8","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan DH","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, et al.. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024, 30:2049-57. 10.1038\/s41591-024-02996-7","journal-title":"Nat Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino F","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al.. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025, 13:221-62. 10.1016\/S2213-8587(24)00316-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1364503","article-title":"Therapeutic advances in obesity management: an overview of the therapeutic interventions","volume":"15","author":"Roomy MA","year":"2024","unstructured":"Roomy MA, Hussain K, Behbehani HM, et al.. Therapeutic advances in obesity management: an overview of the therapeutic interventions. Front Endocrinol (Lausanne). 2024, 15:1364503. 10.3389\/fendo.2024.1364503","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01525-3","article-title":"The past, present, and future of behavioral obesity treatment","volume":"49","author":"Chao AM","year":"2025","unstructured":"Chao AM, Moore M, Wadden TA. The past, present, and future of behavioral obesity treatment. Int J Obes (Lond). 2025, 49:196-205. 10.1038\/s41366-024-01525-3","journal-title":"Int J Obes (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522187-long-term-clinical-outcomes-and-real-world-effectiveness-of-tirzepatide-in-adults-with-overweight-or-obesity-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:07:08Z","timestamp":1787386028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522187-long-term-clinical-outcomes-and-real-world-effectiveness-of-tirzepatide-in-adults-with-overweight-or-obesity-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.114962","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}